Credit Suisse Ag Kura Oncology, Inc. Call Options Transaction History
Credit Suisse Ag
- $101 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding KURA
# of Institutions
185Shares Held
81.8MCall Options Held
42.1KPut Options Held
34K-
Suvretta Capital Management, LLC New York, NY7.65MShares$82.3 Million5.88% of portfolio
-
Black Rock Inc. New York, NY6.97MShares$74.9 Million0.0% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA5.81MShares$62.4 Million4.92% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY5.41MShares$58.2 Million1.97% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY4.33MShares$46.6 Million3.05% of portfolio
About Kura Oncology, Inc.
- Ticker KURA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,893,000
- Market Cap $719M
- Description
- Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A p...